Literature DB >> 7288270

Dysbaric osteonecrosis: a consequence of intravascular bubble formation, endothelial damage, and platelet thrombosis.

S J Slichter, P Stegall, K Smith, T W Huang, L A Harker.   

Abstract

Survival and turnover of platelets, fibrinogen, and plasminogen were measured in association with hyperbaric exposure in man. In addition, kinetic and vascular studies were carried out in a hyperbaric swine model to assess the role of vascular injury and thrombosis in the pathogenesis of dysbaric osteonecrosis. In man, significant increases in platelet and fibrinogen consumption were directly associated with dive depth and with repetitive exposure at lesser depths. The increased destruction of platelets and fibrinogen was not accompanied by reduced blood levels because of compensatory shifts in production rats and distribution between circulating and storage compartments. Platelet consumption was substantially greater than fibrinogen destruction with respect to both severity and duration. Platelet function inhibitors decreased platelet consumption. Increased fibrinogen consumption was sometimes associated with reduced plasminogen survival, but levels of fibrinogen/fibrin degradation products were never measurably altered from normal values. The relationships among platelet and fibrinogen consumption, vascular changes, and dysbaric osteonecrosis were studied in hyperbaric swine. Consumption of hemostatic factors was most severe with rapid, uncontrolled decompression, low oxygen concentrations, and deeper or repetitive dives. Platelet consumption induced by hyperbaric exposure resolved spontaneously with time, suggesting a repair process after the simulated diving conditions were discontinued. Interruption of increased platelet and fibrinogen consumption in the swine model required either moderation of the dive profile or a combination of drugs that inhibit platelet function (dipyridamole or sudoxicam) together with an anticoagulant (warfarin or heparin). Repeated hyperbaric exposure under conditions that uniformly produced femoral osteonecrosis and consumption of platelets and fibrinogen was associated with detectable endothelial injury and arterial intimal lesion formation. Since the diving characteristics of increasing depth and inadequate decompression were associated with both the most severe consumption and the highest frequency of intravascular bubble formation, we postulate that intravascular bubbles, formed during hyperbaria, produce osteonecrosis, perhaps through the following sequence: (1) bubble-related endothelial cell damage; (2) platelet thrombus formation with secondary fibrin deposition; (3) microvascular occlusion; and (4) platelet-dependent arterial narrowing through intimal lesion formation. The role of antithrombotic therapy in the prevention of dysbaric osteonecrosis remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7288270

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

1.  [Hearing impairment in divers].

Authors:  C Klingmann; P K Plinkert
Journal:  HNO       Date:  2005-12       Impact factor: 1.284

2.  Examining the Prospective Scuba Diver: Which Exclusions are Proven?

Authors:  I Beauprie
Journal:  Can Fam Physician       Date:  1989-08       Impact factor: 3.275

Review 3.  [Aseptic necrosis of the femoral head in young adults].

Authors:  H M Vasey
Journal:  Int Orthop       Date:  1984       Impact factor: 3.075

Review 4.  Avascular Necrosis of the Femoral Head: Are Any Genes Involved?

Authors:  Farzaneh Pouya; Mohammad Amin Kerachian
Journal:  Arch Bone Jt Surg       Date:  2015-07

Review 5.  Role of coagulopathy in glucocorticoid-induced osteonecrosis of the femoral head.

Authors:  Qiankun Zhang; Jin L V; Lie Jin
Journal:  J Int Med Res       Date:  2017-05-01       Impact factor: 1.671

Review 6.  Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action.

Authors:  Mohammad Amin Kerachian; Chantal Séguin; Edward J Harvey
Journal:  J Steroid Biochem Mol Biol       Date:  2009-02-21       Impact factor: 4.292

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.